Contact
searchSearch
HMP Global

Peripheral Arterial Disease News

Peripheral Arterial Disease
CIS and Terrebonne General Are First in Louisiana to Use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter
01/09/2026
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA...
01/09/2026
Vascular Disease Management
intravascular lithotripsy
FastWave Medical Names Leading Vascular Specialists as Principal Investigators for Peripheral IVL Trial
10/02/2025
The study will evaluate the safety and effectiveness of the Artero™ IVL system in treating peripheral arterial disease (PAD) and support FastWave's ultimate path to FDA clearance.
The study will evaluate the safety and effectiveness of the Artero™ IVL system in treating peripheral arterial disease (PAD) and support FastWave's ultimate path to FDA clearance.
The study will evaluate the...
10/02/2025
Vascular Disease Management
Retrievable Stents
CIS and Terrebonne General are First in Louisiana to Use the Spur® Peripheral Retrievable Stent System to Treat Artery Disease Below the Knee
06/16/2025
JUNE 16, 2025 – HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the Spur® Peripheral Retrievable Stent System to treat chronic...
JUNE 16, 2025 – HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the Spur® Peripheral Retrievable Stent System to treat chronic...
JUNE 16, 2025 – HOUMA, LA –...
06/16/2025
Vascular Disease Management
VAM25
New Study Finds GLP-1 Medications Decrease Risk of Major Cardiovascular Events and Amputations for Patients With Moderate Peripheral Artery Disease
06/06/2025
NEW ORLEANS, LA, JUNE 6, 2025 – A large retrospective review of over 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of...
NEW ORLEANS, LA, JUNE 6, 2025 – A large retrospective review of over 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of...
NEW ORLEANS, LA, JUNE 6, 2025 –...
06/06/2025
Vascular Disease Management
Drug-Coated Balloons
Cardiovascular Institute of the South Is First in the World to Use New Drug-Coated Balloon to Treat Leg Artery Blockages
05/27/2025
May 24, 2024 – Lafayette, LA – Cardiovascular Institute of the South (CIS) is the first in the world to use the 200-cm RANGER Drug-Coated Balloon to treat peripheral artery disease (PAD) in the legs. CIS interventional cardiologist Dr....
May 24, 2024 – Lafayette, LA – Cardiovascular Institute of the South (CIS) is the first in the world to use the 200-cm RANGER Drug-Coated Balloon to treat peripheral artery disease (PAD) in the legs. CIS interventional cardiologist Dr....
May 24, 2024 – Lafayette,...
05/27/2025
Vascular Disease Management
Lower-extremity intervention
First Patient Treated in ELITE-BTK Pivotal Trial for Below-the-Knee PAD Using R3 Vascular's Magnitude Drug-Eluting Bioresorbable Scaffold
04/22/2025
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its...
04/22/2025
Cath Lab Digest
Restenosis
Real-world Data Shows Cook’s Zilver PTX Leads to Lower Rates of In-stent Occlusion Than Boston Scientific’s Eluvia
03/27/2025
Bloomington, Ind. — Cook Medical’s Zilver PTX drug-eluting stent (DES) has lower rates of in-stent occlusions among patients with restenosis at 3 years than Boston Scientific’s Eluvia DES, according to real-world data from the REALDES study....
Bloomington, Ind. — Cook Medical’s Zilver PTX drug-eluting stent (DES) has lower rates of in-stent occlusions among patients with restenosis at 3 years than Boston Scientific’s Eluvia DES, according to real-world data from the REALDES study....
Bloomington, Ind. — Cook...
03/27/2025
Vascular Disease Management
Critical Limb Ischemia
AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia
01/30/2025
The Auryon laser can be used to treat all infrainguinal lesion types, including above-the-knee (ATK), below-the-knee (BTK) and In-Stent Restenosis (ISR)3-6 and to date, it has been used to treat more than 100,000 patients7 in the United...
The Auryon laser can be used to treat all infrainguinal lesion types, including above-the-knee (ATK), below-the-knee (BTK) and In-Stent Restenosis (ISR)3-6 and to date, it has been used to treat more than 100,000 patients7 in the United...
The Auryon laser can be used to...
01/30/2025
Vascular Disease Management
Bioresorbable Scaffolds
R3 Vascular Secures WCG IRB Approval and CMS Category B Medicare Coverage for the ELITE-BTK Pivotal Trial of its MAGNITUDE Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
01/13/2025
Eric A. Secemsky, MD, MSc, lead investigator for the ELITE-BTK pivotal trial, said, “R3 Vascular’s novel approach in the design of its next generation bioresorbable drug eluting scaffold is of great interest to the physician community and has...
Eric A. Secemsky, MD, MSc, lead investigator for the ELITE-BTK pivotal trial, said, “R3 Vascular’s novel approach in the design of its next generation bioresorbable drug eluting scaffold is of great interest to the physician community and has...
Eric A. Secemsky, MD, MSc, lead...
01/13/2025
Vascular Disease Management
Clot-Sensing Guidewire
Sensome Announces Data From Two New Studies Showing Clot-Sensing Guidewire Successfully Identifies Fresh Clot to Support Decision-Making in Peripheral Artery Disease Treatment
12/13/2024
Data showcased in two late-breaking clinical trial presentations at Paris Vascular Insights Course PARIS – December 13, 2024 – Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced...
Data showcased in two late-breaking clinical trial presentations at Paris Vascular Insights Course PARIS – December 13, 2024 – Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced...
Data showcased in two...
12/13/2024
Vascular Disease Management

Stay in the Know

Vascular Disease Management Newsletter

News

Cardiovascular Scientific Forum
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
02/03/2026
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Physician-led Collaboration...
02/03/2026
Vascular Disease Management
thrombectomy
Penumbra Launches Lightning Flash 3.0 — The Next Evolution in CAVT Technology
01/27/2026
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
Penumbra recently launched the...
01/27/2026
Cath Lab Digest
Acquisitions
Boston Scientific Announces Agreement to Acquire Penumbra, Inc.
01/15/2026
MARLBOROUGH, Mass. and ALAMEDA, Calif. -- Boston Scientific Corporation and Penumbra, Inc., today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock...
MARLBOROUGH, Mass. and ALAMEDA, Calif. -- Boston Scientific Corporation and Penumbra, Inc., today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock...
MARLBOROUGH, Mass. and ALAMEDA,...
01/15/2026
Cath Lab Digest
Peripheral Arterial Disease
CIS and Terrebonne General Are First in Louisiana to Use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter
01/09/2026
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA...
01/09/2026
Vascular Disease Management
Radiation Safety
Rampart Launches SECURE Clinical Program to Advance Clinical Evidence for Next Generation Radiation Protection
01/08/2026
First-of-its-Kind, Multi-Specialty Clinical Initiative Across IC, EP, Endovascular, Aortic, and Neurovascular BIRMINGHAM, Ala. — January 8, 2025 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional...
First-of-its-Kind, Multi-Specialty Clinical Initiative Across IC, EP, Endovascular, Aortic, and Neurovascular BIRMINGHAM, Ala. — January 8, 2025 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional...
First-of-its-Kind,...
01/08/2026
Vascular Disease Management
Deep Venous Disease
Gore Gains FDA Approval for First Deep Venous Stent Indicated for the IVC and Iliofemoral Veins
01/06/2026
The GORE® VIABAHN® FORTEGRA Venous Stent is engineered to offer an optimal balance of conformability and compression resistance for treating a broad range of patients. FLAGSTAFF, Ariz. (January 6, 2026) — W. L. Gore & Associates’...
The GORE® VIABAHN® FORTEGRA Venous Stent is engineered to offer an optimal balance of conformability and compression resistance for treating a broad range of patients. FLAGSTAFF, Ariz. (January 6, 2026) — W. L. Gore & Associates’...
The GORE® VIABAHN® FORTEGRA...
01/06/2026
Vascular Disease Management
Neuro Intervention
Penumbra Receives CE Mark for MIDWAY and ACCESS25 Delivery Catheters in Europe
12/19/2025
MIDWAY 43 and MIDWAY 62 delivery catheters are designed to provide ideal tracking and a stable platform to support the delivery of various embolisation therapies in the neurovasculature.
MIDWAY 43 and MIDWAY 62 delivery catheters are designed to provide ideal tracking and a stable platform to support the delivery of various embolisation therapies in the neurovasculature.
MIDWAY 43 and MIDWAY 62 delivery...
12/19/2025
Vascular Disease Management
Thrombectomy
Study Finds CAVT (Computer-Assisted Vacuum Thrombectomy) Shortens Hospital Stay and May Ease Burden on Hospital Systems
12/16/2025
The research suggests that CAVT, a technology designed to rapidly remove blood clots via microprocessor-controlled aspiration, has the potential to help reduce healthcare costs. 
The research suggests that CAVT, a technology designed to rapidly remove blood clots via microprocessor-controlled aspiration, has the potential to help reduce healthcare costs. 
The research suggests that CAVT,...
12/16/2025
Cath Lab Digest
Intravascular Imaging
Philips Agrees to Acquire SpectraWAVE Inc., Advancing Next-Generation Coronary Intravascular Imaging and Physiological Assessment With AI
12/16/2025
Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled...
Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled...
Acquisition of SpectraWAVE’s...
12/16/2025
Vascular Disease Management
Acute Type A Dissection
Gore Announces First Patient Implant of the GORE® Ascending Stent Graft for Treatment of Acute Type A Dissection in ARISE III Pivotal Study
12/15/2025
The first pivotal trial implant of an investigational endovascular stent graft for the treatment of acute Type A dissections marks a critical milestone.
The first pivotal trial implant of an investigational endovascular stent graft for the treatment of acute Type A dissections marks a critical milestone.
The first pivotal trial implant...
12/15/2025
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use